Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Jena – page 3

349 clinical trials in Jena, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Jena at a glance
349
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

349 trials in Jena

Open in trial search

Follicular lymphoma

Recruiting

Study of AZD0486 plus rituximab versus standard chemotherapy drug combination in previously untreated follicular lymphoma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AstraZeneca AB

Plasma cell myeloma

Recruiting

Cevostamab plus pomalidomide and dexamethasone in patients with multiple myeloma previously treated with BCMA‑targeted CAR T‑cell therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cevostamab
  • Sponsor:F. Hoffmann-La Roche AG

Early switch to oral amoxicillin (drug combination) for adults with vertebral osteomyelitis: a randomised non‑inferiority trial

Recruiting
Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amoxicillin
  • Sponsor:University Of Cologne

Liver transplant

Recruiting

Everolimus-Based Calcineurin-Inhibitor-Free Immunosuppression with Drug Combination in Patients One Year After Liver Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ciclosporin
  • Sponsor:Medizinische Hochschule Hannover

Marginal zone lymphoma+3

Recruiting

Epcoritamab for Adults with Relapsed or Refractory Marginal Zone Lymphoma: A Phase II Open‑Label Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:Universitaetsklinikum Ulm AöR

Plasma cell myeloma

Recruiting

Accelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Small cell lung cancer extensive stage

Recruiting

Study of MK-6070 drug combination in first-line extensive-stage small cell lung cancer patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:Atezolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Crohn's disease

Recruiting

A Phase 3b Study of Guselkumab Compared with Risankizumab in Adults with Moderately to Severely Active Crohn’s Disease

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Guselkumab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer stage III

Recruiting

Pumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Plasma cell myeloma refractory

Recruiting

JNJ-79635322 versus Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma After at Least 3 Prior Treatments

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Teclistamab
  • Sponsor:Janssen Cilag International

Chronic myeloid leukaemia

Recruiting

Long-Term Safety Study of Asciminib in Patients With Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Bosutinib
  • Sponsor:Novartis Pharma AG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Jena

What the registry says about research in the country

01 Oncology Research

Advanced clinical trials focusing on multiple myeloma, prostate cancer, and gastric cancer treatments. Studies evaluating novel therapeutic combinations and targeted approaches for various cancer types.

  • Hematologic Malignancies
  • Solid Tumors
  • Targeted Therapies

Innovative treatments including antibody-drug conjugates and immunotherapy combinations for improved patient outcomes.

02 Cardiovascular Studies

Research investigating treatments for hypertrophic cardiomyopathy and advanced cardiovascular disease. Trials exploring new approaches to reduce major cardiovascular events and improve patient quality of life.

  • Heart Disease Management
  • Cardiovascular Risk Reduction
  • Novel Therapeutic Approaches

Focus on both preventive measures and treatment of established cardiovascular conditions.

03 Autoimmune Disorders

Clinical investigations of treatments for systemic lupus erythematosus, Sjögren's Disease, and other autoimmune conditions. Studies evaluating new biological therapies and targeted treatments.

  • Inflammatory Diseases
  • Immunotherapy
  • Disease-Modifying Treatments

Comprehensive research into improving treatment outcomes for patients with chronic autoimmune conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.